Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Obesity × Pregabalin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1 Breast 1

Conditions

Pain 3 Neuralgia 3 Breast Neoplasms 3 Seizures 1 Pinealoma 1 Oligodendroglioma 1 Obesity 1 Neuroectodermal Tumors, Primitive 1 Neoplasms 1 Myotoxicity 1 Meningioma 1 Medulloblastoma 1 Lymphoma 1 Inflammation 1 Head and Neck Neoplasms 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Ependymoma 1 Earache 1 Drug-Related Side Effects and Adverse Reactions 1 Central Nervous System Neoplasms 1 Brain Neoplasms 1 Astrocytoma 1 Agnosia 1

Interventions

Vitamin D 2 Tirzepatide 2 licogliflozin 1 indole-3-carbinol 1 bupropion hydrochloride, naltrexone hydrochoride drug combination 1 Tablets 1 Specimen Handling 1 Resistance Training 1 Progestins 1 Pregabalin 1 Orlistat 1 Organizational Objectives 1 Omeprazole 1 Observation 1 Naltrexone 1 Metformin 1 Ketorolac 1 Exergaming 1 Exercise 1 Exenatide 1 Diet, Plant-Based 1 Dexmedetomidine 1 Dalteparin 1 Counseling 1 Cholecalciferol 1 Calcium Citrate 1 Calcium Carbonate 1 Calcitriol 1 CKD732 1 Bupropion 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06150898 2025-06-13

KePreSt

Jules Bordet Institute

Phase 2 Recruiting

Breast Neoplasms, Inflammation, Obesity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡